Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation
- PMID:19864936
- DOI: 10.1097/SLA.0b013e3181bdfc27
Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation
Abstract
Objective: The objective of this study was to determine the prevalence and prognostic significance of acellular mucin within resected specimens of rectal cancer patients with a pCR following preoperative chemoradiation.
Summary background data: The presence of acellular mucin pools in the resected specimens of patients with a complete response to preoperative chemoradiation is frequently reported as a marker of treatment effect. The clinical significance of the presence of acellular mucin with respect to local recurrence and survival outcomes is unknown.
Methods: Data from a rectal cancer database was used to analyze 562 patients with nonmetastatic rectal adenocarcinoma treated between 1989 and 2004. The presence or absence of acellular mucin within the specimen was identified by the surgical pathology reports and confirmed by re-examination of H&E sections of surgical specimens.
Results: Among the 562 patients, 100 patients (18%) had pCR. Acellular mucin was present in 27 (27%) of the 100 patients with pCR. The median follow-up interval was 87 months (range, 1-198 months). Local and distant failures occurred in 0 and 2 patients with acellular mucin, and in 1 and 6 patients without acellular mucin, respectively. The actuarial 7-year overall survival rates were 85% for patients with acellular mucin and 92% for patients without acellular mucin (P = 0.954). The actuarial 7-year disease-free survival rates were 81% and 87% (P = 0.764) and the 7-year freedom from relapse rates were 93% and 91% (P = 0.881) in patients with and without acellular mucin, respectively.
Conclusions: Acellular mucin is present within 27% of resected specimens in rectal cancer patients with a pCR after preoperative chemoradiation. However, the presence of acellular mucin has no prognostic significance.
Similar articles
- Clinical implications of acellular mucin pools in resected rectal cancer with pathological complete response to neoadjuvant chemoradiation.de Campos-Lobato LF, Dietz DW, Stocchi L, Vogel JD, Lavery IC, Goldblum JR, Skacel M, Pelley RJ, Kalady MF.de Campos-Lobato LF, et al.Colorectal Dis. 2012 Jan;14(1):62-7. doi: 10.1111/j.1463-1318.2010.02532.x.Colorectal Dis. 2012.PMID:21176057
- Prevalence and clinical significance of acellular mucin in locally advanced rectal cancer patients showing pathologic complete response to preoperative chemoradiotherapy.Lim SB, Hong SM, Yu CS, Hong YS, Kim TW, Park JH, Kim JH, Kim JC.Lim SB, et al.Am J Surg Pathol. 2013 Jan;37(1):47-52. doi: 10.1097/PAS.0b013e3182657186.Am J Surg Pathol. 2013.PMID:23060350
- Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study Group for Therapies of Rectal Malignancies (STORM).Valentini V, et al.Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. doi: 10.1016/j.ijrobp.2005.09.017. Epub 2006 Jan 18.Int J Radiat Oncol Biol Phys. 2006.PMID:16414206Clinical Trial.
- [Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature].Mátrai Z, Lövey J, Hitre E, Orosz Z, Gödény M, Péley G, Sulyok Z, Rényi Vámos F, Farkas E, Köves I.Mátrai Z, et al.Orv Hetil. 2006 Oct 22;147(42):2011-20.Orv Hetil. 2006.PMID:17165600Review.Hungarian.
- Prognostic Role of Acellular Mucin Pools in Patients with Rectal Cancer after Pathological Complete Response to Preoperative Chemoradiation: Systematic Review and Meta-Analysis.Bhatti ABH, Zaheer S, Shafique K.Bhatti ABH, et al.J Coll Physicians Surg Pak. 2017 Nov;27(11):714-718.J Coll Physicians Surg Pak. 2017.PMID:29132485Review.
Cited by
- Rectal cancer: An evidence-based update for primary care providers.Gaertner WB, Kwaan MR, Madoff RD, Melton GB.Gaertner WB, et al.World J Gastroenterol. 2015 Jul 7;21(25):7659-71. doi: 10.3748/wjg.v21.i25.7659.World J Gastroenterol. 2015.PMID:26167068Free PMC article.Review.
- Patterns of recurrence in patients achieving pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer.Fan WH, Xiao J, An X, Jiang W, Li LR, Gao YH, Chen G, Kong LH, Lin JZ, Wang JP, Pan ZZ, Ding PR.Fan WH, et al.J Cancer Res Clin Oncol. 2017 Aug;143(8):1461-1467. doi: 10.1007/s00432-017-2383-9. Epub 2017 Apr 6.J Cancer Res Clin Oncol. 2017.PMID:28386648Free PMC article.
- Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer.Dayde D, Tanaka I, Jain R, Tai MC, Taguchi A.Dayde D, et al.Int J Mol Sci. 2017 Mar 7;18(3):573. doi: 10.3390/ijms18030573.Int J Mol Sci. 2017.PMID:28272347Free PMC article.Review.
- Neoadjuvant chemoradiotherapy determines the prognostic impact of anastomotic leakage in advanced rectal cancer.Oh BY, Park YA, Huh JW, Cho YB, Yun SH, Kim HC, Lee WY.Oh BY, et al.Ann Surg Treat Res. 2022 Oct;103(4):235-243. doi: 10.4174/astr.2022.103.4.235. Epub 2022 Oct 7.Ann Surg Treat Res. 2022.PMID:36304190Free PMC article.
- Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis.Khrizman P, Niland JC, ter Veer A, Milne D, Bullard Dunn K, Carson WE 3rd, Engstrom PF, Shibata S, Skibber JM, Weiser MR, Schrag D, Benson AB 3rd.Khrizman P, et al.J Clin Oncol. 2013 Jan 1;31(1):30-8. doi: 10.1200/JCO.2011.40.3188. Epub 2012 Nov 19.J Clin Oncol. 2013.PMID:23169502Free PMC article.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources